Rimonabant ( DrugBank: Rimonabant )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 2 |
193. Prader-Willi syndrome
Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006305-25-SE (EUCTR) | 15/02/2008 | 03/01/2008 | Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome | Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome | Obese adults with Prader Willi Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10036476;Term: Prader-Willi syndrome MedDRA version: 9.1;Classification code 10029883;Term: Obesity | Trade Name: ACOMPLIA 20 mg film-coated tablets | Karolinska University Hospital | NULL | Not Recruiting | Female: yes Male: yes | Sweden | ||||
| 2 | NCT00603109 (ClinicalTrials.gov) | August 2007 | 15/1/2008 | Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome | Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome. | Prader-willi Syndrome | Drug: rimonabant;Drug: placebo | Weill Medical College of Cornell University | National Institutes of Health (NIH);PWSAUSA | Recruiting | 18 Years | 35 Years | Both | 18 | Phase 3 | United States |